 EMERYVILLE, Calif., Nov. 03, 2020 GLOBE NEWSWIRE -- XOMA Corporation NASDAQ: XOMA, announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies Inc. TSXV:BTI.V; OTCQB:BIOAF, associated with the advancement of the enzymes being investigated as potential treatments for four different lysosomal storage disorders LSD under Bioasis strategic alliance with Chiesi Group. 